Trials / Completed
CompletedNCT02181517
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abicipar pegol | Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8. |
| DRUG | ranibizumab | Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16. |
| OTHER | sham procedure | Sham procedure to the study eye at weeks 12 and 16. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2014-07-04
- Last updated
- 2016-05-17
- Results posted
- 2016-04-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02181517. Inclusion in this directory is not an endorsement.